Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151600 · ClinicalTrials.gov registry record
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
A clinical trial of Peripheral Neuropathy and Neuromuscular Diseases, sponsored by Elpida Therapeutics SPC.
- Recruiting
- Registry status
- 20
- Enrollment target
- 3
- Study locations
NCT06151600: Recruiting study of Peripheral Neuropathy and Neuromuscular Diseases, sponsored by Elpida Therapeutics SPC.
NCT06151600 is a study of Peripheral Neuropathy and Neuromuscular Diseases that is actively recruiting participants, run by Elpida Therapeutics SPC. The registered enrollment target is 20 participants, below the 79-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151600, a study of Peripheral Neuropathy and Neuromuscular Diseases, is actively recruiting participants, sponsored by Elpida Therapeutics SPC.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.
Primary Outcome
This study is designed to investigate the clinical characteristics and natural history of CMT4J.
Conditions Studied
Study Locations (3)
California
- Stanford University - San Francisco
Iowa
- University of Iowa - Iowa City
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2032-03-01 |
What NCT06151600 shows while recruiting
NCT06151600 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 79-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Peripheral Neuropathy appearing as the primary indexed condition, and to 0 interventions.
NCT06151600 reports a single indexed study location in California, Iowa, Texas.
Frequently Asked Questions
What is clinical trial NCT06151600 about?
NCT06151600 is a clinical study titled "A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J". This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks fo...
What is the current status of trial NCT06151600?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-07-29. Estimated completion is 2032-03-01.
What conditions does trial NCT06151600 study?
This clinical trial studies the following conditions: Peripheral Neuropathy, Neuromuscular Diseases, Neuro-Degenerative Disease.
Who is sponsoring clinical trial NCT06151600?
This trial is sponsored by Elpida Therapeutics SPC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06151600 being conducted?
This trial has 3 study locations across California, Iowa, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06151600's enrollment target sits among peer trials
20 23rd of 27 higher than 4 of 27 other Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
RECRUITING
-
Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
DoD AtMS for Posttraumatic Peripheral Neuropathic Pain
RECRUITING · NA
-
Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy
RECRUITING · NA
-
Investigational Use of Neuromuscular Ultrasound
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI